Cipla Limited has informed stock exchanges that the Goods & Service Tax Department, Maharashtra concluded their inspection and search proceedings on February 7, 2026 at 2200 hours (IST). The pharmaceutical company made this disclosure under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, confirming no material impact on the company's financials or operations.

Inspection Timeline and Conclusion

The GST Department inspection, which began on February 5, 2026 at 1230 hours, was successfully concluded within two days. The proceedings were conducted under Section 67 of the Maharashtra Goods & Service Tax Act, 2017, covering both inspection under sub-section (1) and search under sub-section (2).

Company Cooperation and Documentation

Cipla has confirmed that it provided all necessary documents, clarifications and details as requested by the authorities during the inspection process. The company extended full cooperation throughout the proceedings, demonstrating its commitment to regulatory compliance and transparency. Notably, no official document has been issued by the authorities following the conclusion of the inspection.

Impact Assessment

The company has categorically stated that there is no material impact on its financials, operations or other activities due to the inspection and search proceedings. This outcome aligns with the company's earlier assessment when the inspection was initiated, where it had anticipated no financial impact from the proceedings.

Regulatory Compliance

The disclosure was made pursuant to SEBI Listing Regulations and follows the format specified in SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. Company Secretary Rajendra Chopra signed the disclosure document on February 8, 2026, ensuring timely compliance with regulatory requirements for transparency in material events.

Cipla Limited has allotted 8,879 equity shares under its employee stock option schemes, marking another step in its employee compensation programs. The pharmaceutical company informed stock exchanges about this corporate action on January 28, 2026, in compliance with regulatory requirements.

Share Allotment Details

The Operations and Administrative Committee of Cipla approved the allotment of 8,879 fully paid-up equity shares on January 28, 2026. These shares were issued pursuant to the exercise of employee stock options and stock appreciation rights under two specific schemes.

Employee Stock Option Schemes

The share allotment was executed under two employee compensation schemes:

• Employee Stock Option Scheme 2013-A: A long-standing equity compensation program for employees
• Cipla Employee Stock Appreciation Rights Scheme 2021: A more recent scheme offering stock appreciation rights to eligible employees

These schemes are designed to provide equity-based compensation to employees, aligning their interests with shareholders and supporting employee retention.

Impact on Share Capital

Following the allotment, Cipla's capital structure has been updated to reflect the additional shares issued.

Regulatory Compliance

Cipla has notified multiple stock exchanges about this allotment in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed:

• BSE Limited (Scrip Code: 500087)
• National Stock Exchange of India Limited (Scrip Code: CIPLA)
• Societe de la Bourse de Luxembourg

The company also copied Central Depository Services (India) Limited and National Securities Depository Limited on the communication, ensuring all relevant depositories are informed of the capital structure changes.

This allotment represents a routine corporate action as part of Cipla's ongoing employee compensation programs, reflecting the company's commitment to equity-based employee incentives.